https://www.karger.

com/ProdukteDB/Katalogteile/isbn3_8055/_95/_66/prrer0
39_03.pdf
IL-5-directed approaches in the treatment of eosinophil-driven
disease

https://www.ncbi.nlm.nih.gov/pubmed/14523040
Anti-IL-5 treatment reduces deposition of ECM proteins in the
bronchial subepithelial basement membrane of mild atopic
asthmatics

https://www.ncbi.nlm.nih.gov/pubmed/21958585
Mepolizumab, a humanized antiIL-5 mAb, as a treatment option for
severe nasal polyposis

https://www.ncbi.nlm.nih.gov/pubmed/17088140
Nasal IL-5 levels determine the response to antiIL-5 treatment in
patients with nasal polyps

https://www.ncbi.nlm.nih.gov/pubmed/20371394
A review of treatment with mepolizumab, an antiIL-5 mAb, in
hypereosinophilic syndromes and asthma

https://www.ncbi.nlm.nih.gov/pubmed/12765424
Monoclonal anti-interleukin5 treatment suppresses eosinophil but not
Tcell functions

http://eds.a.ebscohost.com/eds/detail/detail?vid=1&sid=11312f10-169049c1-952d-563aa5d59e4d
%40sessionmgr4007&hid=4203&bdata=JkF1dGhUeXBlPWlwLGNvb2tpZSxza
GliLHVpZCZsYW5nPXB0LWJyJnNpdGU9ZWRzLWxpdmUmc2NvcGU9c2l0ZQ
%3d%3d#AN=S0091674913004193&db=edselp

Food, drug, insect sting allergy, and anaphylaxis: AntiIL-5 therapy

reduces mast cell and IL-9 cell numbers in pediatric patients with
eosinophilic esophagitis

http://eds.a.ebscohost.com/eds/detail/detail?vid=2&sid=11312f10-169049c1-952d-563aa5d59e4d
%40sessionmgr4007&hid=4203&bdata=JkF1dGhUeXBlPWlwLGNvb2tpZSxza
GliLHVpZCZsYW5nPXB0LWJyJnNpdGU9ZWRzLWxpdmUmc2NvcGU9c2l0ZQ
%3d%3d#AN=S0091674911013248&db=edselp
Rhinitis, sinusitis, and upper airway disease: Mepolizumab, a
humanized antiIL-5 mAb, as a treatment option for severe nasal
polyposis

https://www.ncbi.nlm.nih.gov/pubmed/21809010
Omalizumab in the treatment of eosinophilic esophagitis and food
allergy.